Nemaura Medical Inc. Stock price

Equities

NMRD

US6404422080

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets 03:32:24 2024-03-28 pm EDT 5-day change 1st Jan Change
0.089 USD +11.11% Intraday chart for Nemaura Medical Inc. +21.58% -59.36%
Sales 2024 * 200K Sales 2025 * 1.4M Capitalization 2.57M
Net income 2024 * -9M Net income 2025 * -12M EV / Sales 2024 * 12.9 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.84 x
P/E ratio 2024 *
-0.28 x
P/E ratio 2025 *
-0.2 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.38%
More Fundamentals * Assessed data
Dynamic Chart
1 day+11.11%
1 week+14.84%
Current month+16.95%
1 month+2.30%
3 months-55.83%
6 months-75.00%
Current year-59.36%
More quotes
1 week
0.07
Extreme 0.0732
0.09
1 month
0.07
Extreme 0.073
0.10
Current year
0.07
Extreme 0.068
0.21
1 year
0.07
Extreme 0.068
1.25
3 years
0.07
Extreme 0.068
17.40
5 years
0.07
Extreme 0.068
17.40
10 years
0.07
Extreme 0.068
96.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 13-12-23
Chief Operating Officer 47 22-01-04
Chief Tech/Sci/R&D Officer 53 -
Members of the board TitleAgeSince
Director/Board Member 49 13-12-23
Chief Executive Officer 50 13-12-23
Director/Board Member 56 17-07-25
More insiders
Date Price Change Volume
24-03-28 0.089 +11.11% 3,464
24-03-27 0.0801 -5.48% 4,605
24-03-26 0.0847 -3.65% 1,351
24-03-25 0.088 +3.69% 1,286
24-03-22 0.0848 +15.87% 24,466

Delayed Quote OTC Markets, March 28, 2024 at 03:32 pm EDT

More quotes
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.089 USD
Average target price
1.5 USD
Spread / Average Target
+1,585.39%
Consensus
  1. Stock
  2. Equities
  3. Stock Nemaura Medical Inc. - OTC Markets